Comparative Pharmacology
Head-to-head clinical analysis: AMCINONIDE versus EXEM FOAM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCINONIDE versus EXEM FOAM KIT.
AMCINONIDE vs EXEM FOAM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
The active ingredient in EXEM FOAM KIT is diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
Apply to affected area twice daily. Exemestane is an aromatase inhibitor; this is a topical formulation.
None Documented
None Documented
Clinical Note
moderateAmcinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin."
Clinical Note
moderateAmcinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin."
Clinical Note
moderateAmcinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin."
Clinical Note
moderateAmcinonide + Trovafloxacin
Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin.
Terminal elimination half-life is approximately 5–6 hours in patients with normal renal function; prolonged in hepatic impairment.
Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates.
Primarily fecal via biliary elimination (>90% as unchanged drug and metabolites); renal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
"The risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin."